Daily biotech dealflow + market tape in 5 minutes — for VC, BD&L, and public biotech investors.
Newsletter
Mar 10, 2026
•
1 min read
Biotech rips as Vertex lands a kidney win, Ipsen pulls Tazverik, and Servier keeps M&A alive with Day One.
Mar 9, 2026
Roche's oral SERD stumbles in first-line breast cancer, GSK monetises linerixibat for $300M upfront, and Xenon delivers a clean Phase 3 epilepsy win.
Mar 6, 2026
Zealand disappoints versus the obesity bar; FDA clears J&J’s Tec-Dara; China approves Pfizer-partnered ecnoglutide.
Mar 5, 2026
Hansa sets a PDUFA date, while MAIA raises $30M in public offering.
Mar 4, 2026
Teva/Blackstone fund TL1A; Sanofi signs a $1.5B JAK/ROCK license; biotech sells off harder than the market.
Mar 3, 2026
FDA clears Intellia’s Phase 3 CRISPR trials to restart, Candid picks a public path with $505M in new money, and uniQure gets a redo request.
Mar 2, 2026
Novartis finishes Avidity, Ascendis lands YUVIWEL approval, and Roche posts a third positive fenebrutinib Phase 3 in MS.
Feb 27, 2026
Generate prints a $400M IPO, Lilly posts a head-to-head win, and ataiBeckley shows an MDMA signal.
Feb 26, 2026
argenx drops positive VYVGART ocular MG topline as deal tape keeps moving (Aicuris, Larimar).
